Focused On-demand Library for Solute carrier family 2, facilitated glucose transporter member 9

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9NRM0

UPID:

GTR9_HUMAN

Alternative names:

Glucose transporter type 9; Urate transporter

Alternative UPACC:

Q9NRM0; Q0VGC4; Q4W5D1; Q8WV30; Q96P00

Background:

Solute carrier family 2, facilitated glucose transporter member 9 (SLC2A9), also known as Glucose transporter type 9 and Urate transporter, plays a pivotal role in urate reabsorption in proximal renal tubules. It exhibits a high-capacity for urate transport, significantly outpacing its glucose transport activity. Additionally, SLC2A9 has a minor role in transporting fructose and adenine, but not galactose or other nucleobases.

Therapeutic significance:

SLC2A9's dysfunction is linked to Hypouricemia renal 2, a disorder marked by impaired uric acid reabsorption leading to high urinary urate excretion. This condition can result in exercise-induced acute renal failure, chronic renal dysfunction, and nephrolithiasis. Understanding the role of SLC2A9 could open doors to potential therapeutic strategies for managing these renal complications.